Filing Analysis
AVITA Medical has issued a warrant certificate to Perceptive Credit Holdings V, LP following stockholder approval at the June 3, 2026 Annual Meeting. This warrant is tied to a previously established $60 million senior secured credit facility.
📋 Key Facts
- Warrant issued on June 5, 2026, to Perceptive Credit Holdings V, LP.
- Initial warrant allows purchase of up to 500,000 shares of common stock at an exercise price of $3.4019.
- An additional 150,000 shares will vest if the company draws the 'Additional Commitment Amount' of $10 million by March 31, 2027.
- The warrant is part of a larger $60 million senior secured credit facility (of which $50 million was already available).
- Warrant shares are being registered via a Form S-3 registration statement and prospectus supplement filed June 5, 2026.
AVITA Medical reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. Stockholders approved the election of directors, the appointment of Grant Thornton LLP as auditor, and several compensation and equity issuance proposals.
📋 Key Facts
- All seven named directors were elected to the Board.
- Grant Thornton LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
- The maximum aggregate annual cash fee pool for non-executive directors was increased from $750,000 to $900,000.
- Stockholders approved the issuance of warrants for up to 650,000 shares of Common Stock to Perceptive Credit Holdings V, LP, related to a credit agreement dated January 13, 2026.
- Approval was granted for the issuance of additional Equity Securities up to 10% of issued capital per ASX Listing Rule 7.1A.
AVITA Medical, Inc. reported its financial results for the first quarter ended March 31, 2026. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the quarter ended March 31, 2026.
- The report was filed on May 14, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release containing the detailed results was furnished as Exhibit 99.1.
- The filing was signed by David O'Toole, Chief Financial Officer.
AVITA Medical has appointed Cary Vance as its permanent President and CEO, effective April 30, 2026, following his service as Interim CEO since October 2025. The company also restructured its board leadership, appointing Jan Stern Reed as Chair of the Board.
📋 Key Facts
- Cary Vance appointed permanent President and CEO effective April 30, 2026.
- Vance's compensation includes a base salary of $702,000 and an 80% target bonus.
- Equity grants totaling approximately $3.35 million ($2,529,000 in RSUs/options and $825,000 in RSUs) are subject to stockholder approval at the 2027 Annual Meeting.
- Jan Stern Reed appointed Chair of the Board, terminating the Lead Independent Director position.
- Vance has 30 years of healthcare leadership experience, including executive roles at GE HealthCare and Covidien.